A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
Testosterone replacement treatment is the most effective way of treating hypogonadism in men.
Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study
will assess the occurrence of skin safety events for a further two months of continuous use
of the Testosterone MD-Lotion® (cutaneous solution) after completion of the MTE08
(NCT00702650) trial.